Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2016American Journal of Hematology

Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMahnur HaiderTulane UniversityNGNaseema GangatMayo Clinic in ArizonaCHCurtis A. HansonToyota Motor Corporation (Switzerland)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Haider et al. (2016) studied this question.

synapsesocial.com/papers/6a827c6ee35fc7ca402a62c7https://doi.org/10.1002/ajh.24334
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia2015 · 274 citations
  2. 2Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients2016 · 39 citations
  3. 3Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)2012 · 606 citations
  4. 4Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management2015 · 269 citations